XORTX Therapeutics Inc. (TSXV:XRTX)
Canada · Delayed Price · Currency is CAD | Market Cap | 5.79M +0.2% |
| Revenue (ttm) | n/a |
| Net Income | -5.31M |
| EPS | -4.01 |
| Shares Out | 1.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 880 |
| Open | 3.200 |
| Previous Close | n/a |
| Day's Range | 3.190 - 3.200 |
| 52-Week Range | 2.425 - 9.850 |
| Beta | 0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About XORTX Therapeutics
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for th... [Read more]
News
XORTX Plans Canadian Trial Of Gout Drug XORLO To Support Future U.S. NDA Filing; Stock Up
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a clinical-stage pharmaceutical company, outlined plans to submit a Clinical Trial Application (CTA) to Health Canada for XORLO (XRx-026), its investigation...
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE...
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
● Clinical Trial Application planned for filing with Health Canada, extending the Company's international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE...
XRTX Therapeutics (XRTX) Advances Gout Treatment Program with IND Submission Plans
XRTX Therapeutics (XRTX) Advances Gout Treatment Program with IND Submission Plans
XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company focused on gout and kidney disease, announced plans to submit an Investigational New Drug application (IND) app...
Xortx Therapeutics announces planned FDA IND submission for XRx-026
XORTX Therapeutics (XRTX) outlines its anticipated Investigational New Drug application, IND, submission to the U.S. Food and Drug Administration, FDA, for the XRx-026 gout program. XORTX’s drug devel...
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026 CALGARY, A...
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company's regulatory path toward NDA filing for gout program XRx-026 Investigat...
XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage pharmaceutical company, is trading higher in overnight trading after announcing the start of drug substance production and tablet manufacturing...
Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo
Xortx Therapeutics (XRTX) announced the launch of production of drug material and tablet manufacturing to support the company’s XRx-026 program for the treatment of gout. This manufacturing supports a...
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEW...
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ●
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX...
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TS...
XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company focused on gout and progressive kidney disease, announced the termination and postponement of its previously an...
Xortx Therapeutics terminates investor relations, marketing agreement
Xortx Therapeutics (XRTX) terminated its previously announced investor relations and marketing agreement dated May 13 with IR Agency LLC. The IR agreement had a 90-day term commencing May 18 and…
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused ...
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused...
XORTX Therapeutics Report: Q2 2026
XORTX Therapeutics published a report on August 14, 2026 containing material business information for investors and shareholders.
XORTX Therapeutics MD&A: Q2 2026
XORTX Therapeutics filed a regulatory document on August 14, 2026 disclosing important business information.
XORTX Announces Director Resignation
CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Appoints New Director
CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Therapeutics Transcript: Transcript
The company is advancing a late-stage gout therapy for allopurinol-intolerant patients, targeting NDA submission within 12-14 months, and preparing to relaunch its ADPKD program. Both programs address large unmet needs, with strong clinical data, robust patent protection, and significant market potential.
XRTX Welcomes Mika Grasso as New Co-CEO for Finance and Public Markets
XRTX Welcomes Mika Grasso as New Co-CEO for Finance and Public Markets
Xortx Therapeutics announces Mika Grasso as co-CEO
Xortx Therapeutics (XRTX) announced the addition of Mika Grasso as co-CEO responsible for finance and public markets. Grasso has served as a director of the company since March 24. Grasso…